



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

LY255283

Cat. No.: HY-15744
CAS No.: 117690-79-6
Molecular Formula: C₁₉H₂₈N₄O₃
Molecular Weight: 360.45
Target: Leukotriene Receptor
Pathway: GPCR/G Protein
Storage: -20°C, stored under nitrogen
 * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (277.43 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		2.7743 mL	13.8715 mL	27.7431 mL
		5 mM		0.5549 mL	2.7743 mL	5.5486 mL
		10 mM		0.2774 mL	1.3872 mL	2.7743 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (6.94 mM); Suspended solution; Need ultrasonic					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (6.94 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.94 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	LY255283 is a LTB ₄ receptor (BLT2) antagonist, with an IC ₅₀ of ~100 nM for [³ H]LTB ₄ binding to guinea pig lung membranes ^[1] [2][3][4].
IC ₅₀ & Target	LTB ₄ ~100 nM (IC ₅₀ , LTB ₄ binds to guinea pig lung membranes)
In Vitro	LY255283 competitively reduces contractile responses of lung parenchyma to LTB, (pA ₂ = 7.2) ^[2] . LY255283 (10 μM, 7 days) significantly suppresses the invasiveness of highly aggressive 253 J-BV bladder cancer cells ^[4] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[4]

Cell Line:	253 J-BV cells.
Concentration:	5 or 10 μ M.
Incubation Time:	7 days.
Result:	Inhibition of BLT2 signaling attenuates aggressive migration by 253 J-BV cells.

In Vivo

LY255283 (3, 30 mg/kg) ameliorates lipopolysaccharide-induced ARDS in pigs, possibly by blocking the recruitment of activated PMNs into alveoli in a dose-dependent fashion^[3].

LY255283 (2.5 mg/kg, ip) inhibits transitional cell carcinoma metastasis in mice models. The result suggests that a BLT2–Nox–ROS–NF- κ B cascade plays a critical role in bladder cancer invasion and metastasis^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice (253 J-BV cells injected) ^[4] .
Dosage:	2.5 mg/kg.
Administration:	IP injected 3 and 5 days after injection of cells.
Result:	By 12 weeks after injection, in mice treated with LY255283 only 0-3 nodules formed per lung, and histological analysis confirmed that the number of micrometastatic lesions was markedly reduced.

CUSTOMER VALIDATION

- J Med Chem. 2022 Jan 7.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. R M Schultz, et al. Effects of two leukotriene B₄ (LTB₄) receptor antagonists (LY255283 and SC-41930) on LTB₄-induced human neutrophil adhesion and superoxide production. Prostaglandins Leukot Essent Fatty Acids. 1991 Aug;43(4):267-71.

[2]. S A Silbaugh, et al. Pulmonary actions of LY255283, a leukotriene B₄ receptor antagonist. Eur J Pharmacol. 1992 Nov 13;223(1):57-64.

[3]. P S Wollert, et al. LY255283, a novel leukotriene B₄ receptor antagonist, limits activation of neutrophils and prevents acute lung injury induced by endotoxin in pigs. Surgery. 1993 Aug;114(2):191-8.

[4]. Eun-Young Kim, et al. BLT2 promotes the invasion and metastasis of aggressive bladder cancer cells through a reactive oxygen species-linked pathway. Free Radic Biol Med. 2010 Sep 15;49(6):1072-81.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA